Novavax, Inc. (Nasdaq: NVAX), a US-based biotechnology company, announced on Wednesday that it has submitted for interim authorisation of NVX-CoV2373, the company's COVID-19 vaccine, under the Pandemic Special Access Route (PSAR) to the Singapore Health Sciences Authority (HAS).
Novavax has made the submission for the regulatory evaluation by HSA of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant.
The filing includes clinical data from two pivotal Phase three clinical trials: PREVENT-19, that included 30,000 participants in the United States and Mexico and showcased 100% protection against moderate and severe disease and 90.4% efficacy; and a trial of 15,000 participants in the United Kingdom that demonstrated efficiency of 96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall. The product is claimed to have showcased a reassuring safety and tolerability profile in both the trials.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma